folder

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study

Authors

  • S. Kayser
  • R.F. Schlenk
  • D. Lebon
  • M. Carre
  • K.S. Götze
  • F. Stölzel
  • A. Berceanu
  • K. Schäfer-Eckart
  • P. Peterlin
  • Y. Hicheri
  • R. Rahme
  • E. Raffoux
  • F. Chermat
  • S.W. Krause
  • W.E. Aulitzky
  • S. Rigaudeau
  • R. Noppeney
  • C. Berthon
  • M. Görner
  • E. Jost
  • P. Carassou
  • U. Keller
  • C. Orvain
  • T. Braun
  • C. Saillard
  • A. Arar
  • V. Kunzmann
  • M. Wemeau
  • M. De Wit
  • D. Niemann
  • C. Bonmati
  • C. Schwänen
  • J. Abraham
  • A. Aljijakli
  • S. Haiat
  • A. Krämer
  • A. Reichle
  • M. Gnadler
  • C. Willekens
  • K. Spiekermann
  • W. Hiddemann
  • C. Müller-Tidow
  • C. Thiede
  • C. Röllig
  • H. Serve
  • M. Bornhäuser
  • C.D. Baldus
  • E. Lengfelder
  • P. Fenaux
  • U. Platzbecker
  • L. Adès

Journal

  • Haematologica

Citation

  • Haematologica

Abstract

  • The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (APL; median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide (ATO) and alltrans retinoic acid (ATRA). All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. APL was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after start of therapy. With a median follow-up of 1.99 years (95%-CI, 1.61-2.30 years) 1-year and 2-years overall survival (OS) rates were 97% (95%-CI, 94-100%) and 95% (95%-CI, 91-99%), respectively. Age above 70 years was associated with a significantly shorter OS (P<0.001) as compared to younger patients. So far no relapses were observed. Six patients (4%) died in CR after in median 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of ATO/ATRA in the primary management of adult low-/ intermediate-risk APL patients in the real life setting, irrespective of age.


DOI

doi:10.3324/haematol.2021.278722